Nektar Therapeutics
NKTR
260 hedge funds and large institutions have $4.05B invested in Nektar Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 75 increasing their positions, 96 reducing their positions, and 23 closing their positions.
78% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 23
27% more capital invested
Capital invested by funds: $3.19B → $4.05B (+$868M)
7% more funds holding
Funds holding: 244 → 260 (+16)
9% more call options, than puts
Call options by funds: $23.7M | Put options by funds: $21.8M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.52% less ownership
Funds ownership: 99.87% → 98.35% (-1.5%)
22% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 96
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$18.2M |
| 2 |
BlackRock
New York
|
+$12.8M |
| 3 |
D.E. Shaw & Co
New York
|
+$10.6M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$6M |
| 5 |
Two Sigma Investments
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
-$22.4M |
| 2 |
M&T Bank
Buffalo,
New York
|
-$18.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$15.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.94M |
NKTR Hedge Fund Activity: Q2 2020 in Review
260 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2020, worth a combined $4.05B — up 27% from $3.19B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new NKTR positions and 23 closed out — a net gain of 18 holders — while 75 added to existing stakes and 96 trimmed.
The largest buyer was First Trust Advisors, adding an estimated $18.2M. The largest seller was Primecap Management, cutting an estimated $22.4M.
- 260 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2020, up from 244 in Q1 2020.
- Funds reported $4.05B of Nektar Therapeutics stock for Q2 2020, up 27% quarter-over-quarter.
- 41 funds opened new Nektar Therapeutics positions in Q2 2020 and 23 closed out, a net change of +18 holders.
- The largest Nektar Therapeutics buyer in Q2 2020 was First Trust Advisors, an estimated $18.2M added.
- The largest Nektar Therapeutics seller in Q2 2020 was Primecap Management, an estimated $22.4M sold.
Based on aggregated 13F filings for Q2 2020.